Pharmaceutical

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Jul 1, 2023 - 20:00
[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Read the original article

Tags:

Previous Article

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

Next Article

KP-910 by Kaken Pharmaceutical for Peripheral Neuropathic Pain: Likelihood of Ap...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pharma Fix: The quest for the next tuberculosis vaccine

Pharma Fix: The quest for the next tuberculosis vaccine

Mar 25, 2023

STAT+: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado

STAT+: Amgen’s rheumatoid arthritis drug Enbrel targete...

Feb 23, 2024

Physicians highlight need for improved non-opioid treatments for opioid use disorder

Physicians highlight need for improved non-opioid treat...

Sep 28, 2024